Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis

Seung Hun Kang1, Hyun Seon Kim1, Myoung Nam Bae1

  • 1Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Insights

Posaconazole prophylaxis can fail, leading to fatal mucormycosis in leukemia patients. This case highlights posaconazole

Area of Science:

  • Mycology
  • Infectious Diseases
  • Hematology

Background:

  • Posaconazole is a broad-spectrum triazole antifungal.
  • It is used for prophylaxis against invasive fungal infections in neutropenic patients, particularly those with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).
  • Posaconazole has demonstrated superior efficacy over fluconazole and itraconazole in preventing fungal infections.

Purpose of the Study:

  • To report the first case of fatal breakthrough mucormycosis in Korea.
  • To highlight the limitations of posaconazole prophylaxis against certain fungi.

Main Methods:

  • Case report of a patient undergoing remission induction chemotherapy for AML.
  • The patient received posaconazole prophylaxis.
  • The patient developed and succumbed to mucormycosis.

Main Results:

  • A patient on posaconazole prophylaxis developed fatal mucormycosis.
  • This represents a breakthrough fungal infection despite appropriate prophylaxis.
  • The limited activity of posaconazole against Mucorales was implicated.

Conclusions:

  • Posaconazole prophylaxis may not be fully effective against all invasive fungal infections.
  • Breakthrough mucormycosis can occur even with posaconazole use.
  • Physicians should be aware of posaconazole's limitations, especially against Mucorales in high-risk patients.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
97
Fungal Group Zygomycota01:29

Fungal Group Zygomycota

Zygomycota, previously classified as a distinct fungal group, are primarily terrestrial, saprophytic molds that play a crucial role as decomposers. Recent phylogenetic studies have revealed that these fungi are now divided into two major clades — Mucoromycota, which includes many symbiotic species, and Zoopagomycota, which primarily consists of parasitic and pathogenic fungi. These groups exhibit distinct ecological roles and reproductive strategies while sharing key structural and...
2.1K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K